N,N-dimethyltryptamine (DMT) is a psychoactive substance with similar effects such as LSD or psilocybin. However, DMT is less well characterized than the latter substances. The present study is a modern randomized cross-over trial, investigating different continuous intravenous DMT dose rates over a broad dose range. Thus, different doses will be tested and ...
Who will staff the psychedelic resurgence? Who will staff the psychedelic resurgence? Erika Dyck, Professor and Canada Research Chair in History of Health & Social Justice from the University of Saskatchewan, provides an intriguing answer to this question. On 6th February 2024, a research team at Le Grau-du-Roi Hospital in the south of France, led by addicto...
LSD, psilocybin and mescaline are widely used for recreational and ethnomedical purposes. All three substances are thought to induce prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor. However, there are differences in the substances' molecular structures and receptor activation profiles which may induce differential subjective...
This open-label fMRI study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with treatment-resistant major depressive disorder.
Back to table of contents Previous article Next article Clinical & ResearchFull AccessAustralia Legalizes Psychedelics for Use in Depression, PTSD TherapyNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:15 Aug 2023https://doi.org/10.1176/appi.pn.2023.09.9.20AbstractThe country is the first to make psilocybin and MDMA available ...
Mescaline (the active substance in Peyote and San Pedro cacti) is a classic and long known serotonergic psychedelic substance (hallucinogen) that is widely used for recreational, spiritual, and/or ethno medical purposes. Despite its long history, modern data on the acute effects of mescaline on human is lacking. Mescaline produces prototypical psychedelic ef...
Background: Psilocybin has been suggested as a novel, rapid-acting treatment for depression. Two consecutive doses have been shown to markedly decrease symptom severity in an open-label setting or when compared to a waiting list group. To date, to our knowledge, no other trial compared a single, moderate dose of psilocybin to a placebo condition. Methods: In...
Background: Lysergic acid diethylamide (LSD) was extensively investigated in humans in the 1950s and 1960s. Particularly, LSD attenuated anxiety in patients with cancer. Clinical research with LSD ended in the 1970s due to regulatory restrictions but its use for personal and recreational purposes continued. In recent years, there has been a renewed interest ...
Back to table of contents Previous article Next article ViewpointsFull AccessPsychedelic Drugs for Mental Disorders and Human Potential: Placebo or PanaceaDavid Hellerstein, M.D., Kevin Sabet, Ph.D., Jeffrey A. Lieberman, M.D.David HellersteinSearch for more papers by this author, M.D., Kevin SabetSearch for more papers by this author, Ph.D., Jeffrey A. Lieb...
LSD (lysergic acid diethylamide) and psilocybin (the active substance in "magic mushrooms") are widely used for recreational purposes. Both substances are also increasingly used in psychiatric and psychological research to induce and investigate alterations in waking consciousness and associated brain functions (functional brain imaging, "model psychosis"). ...
Psilocybin is a classic serotonergic hallucinogen acting on the 5-HT2A receptor. It is used recreationally and in psychiatric research. Selective serotonin reuptake inhibitors (SSRIs) like escitalopram are first-line treatments for depression. They inhibit the serotonin transporter (SERT). This might cause a possible downregulation of postsynaptic 5-HT recep...
Back to table of contents Previous article Next article Clinical & ResearchFull AccessCan Psychedelics Radically Change SUD Treatment?Katie O'ConnorKatie O'ConnorPublished Online:20 Mar 2020https://doi.org/10.1176/appi.pn.2020.2a12AbstractThough the field is young, psychedelics appear to hold promise as a treatment for addiction, even as barriers to research...
Back to table of contents Previous article Next article ProfessionalFull AccessJohns Hopkins Opens Research Center on PsychedelicsNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:28 Oct 2019https://doi.org/10.1176/appi.pn.2019.10a16AbstractA total of $17 million in private donations to the Hopkins center is expected to provide ...
The psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological support, have indicated improvements in mood, anxiety and quality of life. A seminal, open-label study demonstrated marked reductions in depression symptoms in participants with treatment-resistant depression (TRD...
This is a pilot study to finalize methods for a larger study being planned for the future. This research is being done to characterize performance of tasks, brain functioning, and the effects of psilocybin in individuals with a long-term meditation practice. There are three different parts of the pilot study: 1. Effects of psilocybin on psychological functio...
In the past 10 years from 1991 to 2000, the number of consultations to the Japan Poison Information Center were 947 concerning mushroom poisonings. However, those from the hospital cases were not analyzed toxicologically. We examined toxicologically 20 cases (35 patients) of mushroom poisonings from 1993 to 2001. Investigation of amanita toxin poisoning was ...
